AU770392B2 - Companion animal therapeutic treat - Google Patents
Companion animal therapeutic treat Download PDFInfo
- Publication number
- AU770392B2 AU770392B2 AU49694/99A AU4969499A AU770392B2 AU 770392 B2 AU770392 B2 AU 770392B2 AU 49694/99 A AU49694/99 A AU 49694/99A AU 4969499 A AU4969499 A AU 4969499A AU 770392 B2 AU770392 B2 AU 770392B2
- Authority
- AU
- Australia
- Prior art keywords
- dosage form
- jerky
- sea cucumber
- fractions
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
WO 00/01399 PCT/US99/15168 COMPANION ANIMAL THERAPEUTIC TREAT Field of the Invention The present invention involves the use of sea cucumber tissue fractions, in combination with kelp, and/or green tea extracts, for the inhibition of inflammation. These therapeutic fractions are incorporated with ingredients which provide palatability into a delivery system as a userconvenient and pet acceptable "jerky stick" or similar animal "treat" format.
Backaround of the Invention Dogs and other companion animals suffering from various forms of arthritis are in need of supplements which deliver active forms of anti-inflammatory agents in a palatable manner.
Glucosamine sulfate and glucosamine HCL and related products are described in various patents such as those by Henderson, et al, which teach the incorporation of glucosamines with other sulfated polysaccharides, vitamin C and manganese in products aimed at cartilage health. It is believed that glucosamine, or similar products, provide one or more of the biochemical components which make up the matrix of mammalian cartilage. Glucosamine is a .U WnW IrM~thl~~ *P!X"ijh' ~F WO 00/01399 PCT/US99/15168 2 chondroprotective agent which acts as a competitive inhibitor of inflammatory agents produced by the body which attack the cartilage and/or joint fluid in the joints.
Green tea extracts have been shown to be potent inhibitors of inflammation and collagen-induced arthritis in mice. See, Haqqi, et al., Proc. Natl.
Acad. Sci., USA, 96:4524-29 (1999). The polyphenolic subfraction of green tea, known as epigallocatechin-3gallate (EGCg), has proven to be an inhibitor of cartilage degradation in mammals. Id. In an experiment, purified EGCg, from Sigma Chemical Supply, St. Louis, MO, was placed with bovine nasal cartilage explants at a concentration of 22pM. This mixture was cultured for 5 days in the presence or absence of the pro-inflammatory cytokine, recombinant human tumor necrosis factor alpha at 3nM. The inhibition of both the basal and stimulated protcoglycan degradation by EGCg was measured using a colorimetric assay for sulfated glycosaminoglycans. See, Farndale, et al., Biochem. Biophys. Acta, 4:883 (1986). The results showed that EGCg was a potent inhibitor of cartilage breakdown at the sub-cellular level.
Jerky sticks, as are known in the dog treat industry, are often combinations of meat or fish byproducts, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols that are mixed and extruded into various shapes, weights, and sizes which can vary widely. See, U.S. patent No. 5,773,076 for a general description of the art. Jerky sticks are given to pets as rewards or for added nutrition, or both.
Both extracts from the sea cucumber and from green tea are known to have beneficial therapeutic effects in mammals. These beneficial effects could not be utilized by veterinarians and others skilled in the art of animal care because they were not available in a palatable form. It is known to those skilled in the art of veterinary science that dogs and other mammals prefer palatability factors such as, fish, meat or meat by-products to enhance the attractiveness of therapeutic products and increase patient compliance.
Given the lack of a mode of delivery for these types of anti-inflammatory extracts that is both easy to administer for the caretaker and agreeable to the animal, there is a recognized need for the combination of an acceptable delivery form and the therapeutic extracts.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Summary of the Invention The present invention relates to a mode of delivery for biologically active fractions of sea cucumber. In a preferred embodiment, the present invention describes a "jerky stick" or "dog bone" as is known in the art, being combined with the palatability factors of meat and meat by-products, garlic, smoke flavour or cheese, and the additional co-factors of glucosamine sulphate, glucosamine hydrochloride and/or green tea extracts or derivatives thereof for therapeutic treatment of inflammation and arthritis.
0In one aspect, the present invention is directed to a dosage form for S•administering therapeutic agents to non human animals in need thereof comprising one or more fractions of sea cucumber in percentages of incorporation between 1 and by weight of the total, glucosamine or salts thereof in percentages of incorporation 30 between 1 and 90% by weight of the total and one or more palatability factors in an effective amount to render the composition palatable to said non human animals, wherein said dosage form is a jerky treat and weighs between 1 and 30 grams.
0* •In another aspect, the present invention is directed to a method of delivery of *o one or more sea cucumber fractions to non human animals by the administration of a 35 jerky treat dosage form which contains an effective amount of said one or more sea cucumber fractions.
0:00* In yet another aspect, the present invention is directed to a method to provide increased mobility and relieve nutritional and arthritic or inflammatory symptoms in a non human animal in need of same by administering a combination of glucosamine or salts thereof and sea cucumber fractions, at percentages of each of and (2) between 1% and 90% by weight of the total to said animal and wherein and are administered in a jerky treat dosage form.
In yet a further aspect, the present invention is directed to a jerky stick dosage form for administering therapeutic agents to non human animals in need thereof comprising an effective amount of one or more sea cucumber fractions.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Detailed Description of the Invention Preferably, the non human animal is a domestic animal, more preferably a dog.
Preferably, the sea cucumber fraction delivery system for animals of the present invention includes the combination of glucosamines and/or kelp, and/or green tea extracts in the form, of a jerky stick, or "treat", as is popular in the dog-treat industry.
The "jerky stick" of the present invention combines certain ingredients and is made palatable by certain co-factors such as meats or flavourings known to those skilled in the art and preferably includes glucosamines or glucosamine derivatives. Sea cucumber body wall finely divided, including the epithelial layer, muscle layer and collagen layer as an ingredient in a formed dog jerky stick is also an aspect of the present invention. These total sea cucumber skin fractions are also incorporated with 25 glucosamines described above and formed in various percentages of incorporation into jerky sticks with palatability factors such as meat e.g. beef, meat meal and meat byproducts, fish by-products, garlic, smoke flavour, cheese and Norwegian kelp or other flavour-bearing compounds. A suitable range of glucosamine concentration is between 1% and 50% of the final product (by weight). These jerky sticks or manufactured 30 "treats" are administered to dogs, cats and other animals and provide increased attractiveness to those animals in need of the therapeutic ingredients.
As used herein, the term "B 1000" refers to the isolated epithelial layer of the sea cucumber, *o oe o WO 00/01399 PCTIUS99/15168 substantially free of the flower portion, muscle, collagenous tissues and viscera; the term "T2000" refers to the isolated flower portion of the sea cucumber, substantially free of other portions of the sea cucumber body; the term "derivative" refers to any compound, fraction or combination thereof, derived from a sea cucumber or green tea fraction that has biological activity or nutritional properties; the term "inflammation disorder" refers to any condition or disease in a warm-blooded animal having inflammation as a symptom or proximate cause.
In one embodiment of the invention the delivery form "jerky treat" material contains the sea cucumber fractions as disclosed in U.S. patent No. 5,770,205.
Active anti-inflammatory compositions can be obtained from sea cucumber in a variety of ways. For example, sea cucumbers can first be cleaned of muscle bands and viscera, boiled (but not salted), preferably for about hour, and then dried, preferably in low-heat mechanical driers such as those employing "heat pump" technology. The dried tissue can further be ground or divided as needed for ultimate use. This process decreases the sodium content of the tissue and helps protect various active ingredients from degradation.
This fraction can be formulated and used directly as an anti-inflammatory composition.
Another active fraction can be obtained from the flower portion of the sea cucumber. During the evisceration process described above, the anterior portion ("flower") of the sea cucumber is cut away from the viscera and body wall. The isolated flower is then .~rwi~i.~6~u;uuiilL~\~M Nil-~hh~~i~r~laa WO 00/01399 PCTIUS99/15168 6 heated, preferably for about hour, dried at low temperatures (e.ga. between about 140°F and about 180°F using.conventional drying apparatus and per se known techniques). This dried fraction, designated "T2000" by the inventor, can then be ground or divided as needed for formulation and use directly as an antiinflammatory composition.
Still another anti-inflammatory fraction can be obtained from the epithelial layer of the sea cucumber body wall. Muscle, viscera and flower are removed as described above, followed by isolation of the epithelial layer of the sea cucumber body wall from the harder collagenous layers beneath, preferably by one or more of the following means: heating the body-wall in water at temperatures from about 140°F to about 180°F, preferably at about 170F, followed by mechanical separation by hand or machine using machines known in the art as mincers or de-boners, which detect tissue density and separate harder tissues from softer tissues); enzymatic hydrolytic separation, using, organism's own digestive tract enzymes, proteases from mammalian sources, proteases from nonmammalian sources or acidic hydrolazes, preferably Alcalase (NOVO Nordisk Bio Chem, North Carolina), the enzyme preferably being in a solution of about 1% to about 10% enzyme, most preferably in a solution of about 10% enzyme; scouring/scrubbing or de-boning processes known to those skilled in the potato or chicken processing arts.
11010 4M W WO 00/01399 PCTIUS99/15168 7 Heating in water, followed by mechanical separation using a de-boner is most preferred.
The epithelial fraction so obtained (designated "B1000" by the inventor) is a dark, moist, viscous, carbohydrate-rich matter. B1000 can be dried as described above, formulated and used directly as an anti-inflammatory composition.
Once produced, the B1000 and/or T2000 fractions, other sea cucumber tissues, and kelp, are incorporated into the mixture for the preparation of the "jerky treats" in amounts between 1% and 80% by weight. These therapeutic constituents are then added to the combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols and palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds that are mixed and extruded into various shapes, weights, and sizes which can vary widely.
In another embodiment of the invention, green tea or green tea extracts are added to the formulation.
Green tea is known to contain potent inhibitors of cartilage degradation, for example EGCg, and is a useful adjunct for treating individuals with inflammatory diseases, such as arthritis, that can lead to cartilage degradation. Green tea can be water and alcohol extracted by methods known in the art whereby the phenolic fraction is between 30% and 70%. Green tea extracts having 30%, 50%, 60% and 100% enriched polyphenolics, or specifically green tea catechins, are available commercially and are suitable for use in the present invention. Extracts are incorporated into the 4. MNOWYON WOMUNKA iM, i WlAA! MAiwsw WO 00/01399 PCT/US99/15168 8 "jerky stick" of the present invention at percentages of weight between 1% and 80% of the total "jerky stick" delivery form. Alternatively, the pure compound EGCg can be added directly to the "jerky stick" formulation in amounts ranging up to 60% by weight or more, limited by factors such as LDo 0 and the physical considerations of maintaining a palatable consistency to the product.
Example 1 Preparation of the "Jerky Stick" With Sea Cucumber and Kelp Fractions Jerky sticks were prepared using T2000 from the Sea Cucumber, Cucumaria frondosa, as described above.
T2000, together with various palatability factors including, but not limited to, meat, meat by-products and "Norwegian" kelp, Ascophylum nodosum, were added to vitamin E, garlic, lecithin, gelatin, glucosamine (as a hydrochloride salt, although the sulfate salt or any other suitable form) and flax seeds. The T2000 was added at about 8% of the final treat product by weight.
The glucosamine constituent was added at 2% of the final treat product by weight. The ingredient mix was then extruded and molded into a jerky stick shape inches long, 1.25 inches wide and approximately 0.25 inches thick, with final weight of 14 grams.
fillOWWWOM VA",*V%,AA~rNOO WHI T WO 00/01399 PCT/US99/15168 9 Example 2 Preparation of the "Jerky Stick" With Additional Green Tea Fractions The jerky stick was produced as in Example 1, with the addition of a green tea extract containing polyphenolics. The green tea extract, purchased from Indena USA. Seattle WA, USA, Product 36TVD0090-"THE VERT" AQ-ATO-HF, was added to the above recipe at 2% by weight, but can be added at any percentage of the jerky stick weight between 1% and 30% (limited by palatability). This provided an effective dose of 280 milligrams of the green tea extract to the jerky product. It is contemplated that the epigallocatechin- 3-gallate (EGCg) is absorbed systemically in mammals, and is effective in inhibiting degradation of cartilage in arthritic joints. In addition, EGCg is thought to provide added synergy to the anti-inflammatory activity of the sea cucumber and the sea cucumber plus glucosamine compounds.
Example 3 Effectiveness and Palatability of the "Jerky Stick" in Arthritic Dogs Jerky sticks with added green tea extracts were administered to 4 dogs of unknown breeds at Westside Animal Clinic in Richmond, IN and were found to be palatable.
Further, six arthritic dogs in various conditions of lameness were administered jerky sticks as prepared in Example 1. After two weeks of administration at one &lh Aiww v..Avttw.qt*IAW",gr A4,AIMKvmvwk#me". IVIV$Mti ii' W a #W0111NOA A luffilljoraw. pf"A*100 1%.Whwvo VOR 4*04OPP91 AvrNWI vA -AXIO mm'61A, m rmw Rv 10 1f1Vh;1MAO1 WO 00/01399 PCT/US99/15168 stick per day per 50 pounds of weight, these dogs showed increased mobility as determined by both their owners and veterinarians. In every instance, palatability was not a problem in administration of the jerky.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons of ordinary skill in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
4 W.
Claims (21)
1. A dosage form for administering therapeutic agents to non human animals in need thereof comprising one or more fractions of sea cucumber in percentages of incorporation between 1 and 90% by weight of the total, glucosamine or salts thereof in percentages of incorporation between 1 and 90% by weight of the total and one or more palatability factors in an effective amount to render the composition palatable to said non human animals, wherein said dosage form is a jerky treat and weights between 1 and 30 grams.
2. A method of delivery of one or more sea cucumber fractions to non human animals by the administration of a jerky treat dosage form which contains an effective amount of same one or more sea cucumber fractions.
3. A method to provide increased mobility and relieve nutritional and arthritic or inflammatory symptoms in a non human animal in need of same by administering a combination of glucosamine or salts thereof and sea cucumber fractions, at percentages of each of and between 1% and 90% by weight of the total to said animal and wherein and are administered in a jerky treat dosage form.
4. A dosage form of claim 1, additionally comprising green tea extract in an effective amount to inhibit inflammation in mammal in need of same.
The dosage form of claim 1 comprising said one or more fractions of sea cucumber in percentages of incorporation between 1% and 80% by weight, and said glucosamine salt in the form of glucosamine HCI or glucosamine sulfate in percentages of incorporation between 1 and 50% by weight.
6. The dosage form of claim 1, wherein said non human animal is a domestic animal.
7. The dosage form of claim 1, wherein said dosage form is a jerky stick.
8. The method of claim 3, wherein said non human animal is a domestic animal.
9. The dosage form of claim 6, wherein said domestic animal is a dog.
The method of claim 8, wherein said domestic animal is a dog.
11. The dosage form of claim 1, wherein said palatability factors are derived from 30 meat, meat by products, meat meal, fish by products, garlic, smoke flavour, cheese or Norwegian kelp.
12. The dosage form of claim 1, wherein the dosage form is a jerky stick.
S13. The method of claim 3, wherein jerky treat dosage form is a jerky stick.
14. The dosage form according to claim 1, wherein one or more of said fractions are 35 derived from the epithelial layer and/or flower portion of sea cucumber.
Arv W WWW 01 %wokiffi AMP 1 R OMIN NWANiI O NW1I VW VW WAIAT& a) i 4 in N p VA 11MOI&M 12 The dosage form according to claim 4, wherein the green tea extract has 60% and 100% enriched polyphenolics.
16. A dosage form according to claim 4, wherein the green tea extract comprises one or more green tea catechins.
17. A dosage form according to claim 4, wherein the green tea extract comprises pure EGCg.
18. The method of claim 2, wherein said jerky treat dosage form is a jerky stick.
19. The method of claim 2, wherein said jerky treat dosage comprises glucosamine or salts thereof in percentages of incorporation between 1 and 90% by weight of the total.
A jerky stick dosage form for administering therapeutic agents to non human animals in need thereof comprising an effective amount of one or more sea cucumber fractions.
21. A dosage form for administering therapeutic agents to non human animals substantially as hereinbefore described with reference to Examples 1 or 2. Dated this tenth day of December 2003 Coastside Bio Resources Patent Attorneys for the Applicant: F B RICE CO o o. o* *•go o *o*
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9441898P | 1998-07-07 | 1998-07-07 | |
| US60/094418 | 1998-07-07 | ||
| US13769999P | 1999-06-07 | 1999-06-07 | |
| US60/137699 | 1999-06-07 | ||
| PCT/US1999/015168 WO2000001399A1 (en) | 1998-07-07 | 1999-07-06 | Companion animal therapeutic treat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU4969499A AU4969499A (en) | 2000-01-24 |
| AU770392C AU770392C (en) | 2000-01-24 |
| AU770392B2 true AU770392B2 (en) | 2004-02-19 |
Family
ID=26788849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU49694/99A Ceased AU770392B2 (en) | 1998-07-07 | 1999-07-06 | Companion animal therapeutic treat |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2002519384A (en) |
| AU (1) | AU770392B2 (en) |
| CA (1) | CA2336602C (en) |
| GB (1) | GB2355196B (en) |
| WO (1) | WO2000001399A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
| NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| JP2003531597A (en) | 2000-05-01 | 2003-10-28 | ジ・アイアムズ・カンパニー | Method for enhancing canine immune response using garlic-containing feed composition |
| US6916492B2 (en) | 2001-03-30 | 2005-07-12 | Council Of Scientific & Industrial Research | Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses |
| US6689391B2 (en) | 2001-03-30 | 2004-02-10 | Council Of Scientific & Industrial Research | Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses |
| US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
| JP4757413B2 (en) * | 2001-09-11 | 2011-08-24 | 株式会社高研 | Sponge made of sea cucumber or starfish collagen and method for producing the same |
| FR2831396B1 (en) * | 2001-10-31 | 2004-04-02 | Moulin Du Chatel | FOOD FOR LAYING HENS FOR THE PRODUCTION OF IODIZED AND POLYUNSATURATED FATTY EDIBLE EGGS AND PROCESS FOR SUPPLYING CORRESPONDING LAYING HENS |
| KR20050108423A (en) * | 2003-04-11 | 2005-11-16 | 교와 핫꼬 고교 가부시끼가이샤 | Preventive or remedy for arthritis |
| CN102934819B (en) * | 2012-10-26 | 2014-04-02 | 青岛佳日隆海洋食品有限公司 | Trepang capsule and preparation process thereof |
| GB201414910D0 (en) * | 2014-05-23 | 2014-10-08 | Mars Inc | Composition |
| KR102694404B1 (en) * | 2024-02-14 | 2024-08-13 | 주식회사 래디안 | Anti-inflammatory composition for pets, Manufacturing method thereof and Cosmetic materials for pets |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770205A (en) * | 1996-08-05 | 1998-06-23 | Coastside Bio Resources | Tissue fractions of sea cucumber for the treatment of inflammation |
| AU7601198A (en) * | 1997-05-23 | 1998-12-11 | Bernard Weisman | Natural composition for treating bone or joint inflammation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1044707B (en) * | 1968-10-26 | 1980-04-21 | Rotta Research Lab | PROCEDURE FOR THE PREPARATION OF GLUCOSANINE SALTS AND PHARMACEUTICAL PREPARATIONS INCLUDING THESE GLUCOSAMINE SALTS AS ACTIVE AGENTS |
| US4975270A (en) * | 1987-04-21 | 1990-12-04 | Nabisco Brands, Inc. | Elastomer encased active ingredients |
| JPH0491027A (en) * | 1990-08-02 | 1992-03-24 | Taiho Yakuhin Kogyo Kk | Anti-human immunodeficiency virus agent |
| JPH04117329A (en) * | 1990-09-05 | 1992-04-17 | Shiseido Co Ltd | Composition showing activity related to dissolution of thrombosis |
| CN1050680A (en) * | 1990-10-05 | 1991-04-17 | 刘辉明 | The manufacture method of Haicibao liquid |
| CN1045538C (en) * | 1993-08-04 | 1999-10-13 | 成都市疑难病研究所 | Natural composition oral medicine for treating male sterility |
| US5474033A (en) * | 1994-05-05 | 1995-12-12 | Mitchell, Jr.; Robert K. | Animal teaching/amusement device |
| US5464619A (en) * | 1994-06-03 | 1995-11-07 | The Procter & Gamble Company | Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability |
| FR2745978B1 (en) * | 1996-03-18 | 1998-07-17 | ORAL TREATMENT PRODUCT FOR ANIMALS |
-
1999
- 1999-07-06 AU AU49694/99A patent/AU770392B2/en not_active Ceased
- 1999-07-06 JP JP2000557845A patent/JP2002519384A/en not_active Withdrawn
- 1999-07-06 CA CA2336602A patent/CA2336602C/en not_active Expired - Fee Related
- 1999-07-06 WO PCT/US1999/015168 patent/WO2000001399A1/en not_active Ceased
- 1999-07-06 GB GB0100640A patent/GB2355196B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770205A (en) * | 1996-08-05 | 1998-06-23 | Coastside Bio Resources | Tissue fractions of sea cucumber for the treatment of inflammation |
| AU7601198A (en) * | 1997-05-23 | 1998-12-11 | Bernard Weisman | Natural composition for treating bone or joint inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2336602C (en) | 2010-11-02 |
| GB2355196B (en) | 2004-06-09 |
| GB0100640D0 (en) | 2001-02-21 |
| WO2000001399A1 (en) | 2000-01-13 |
| GB2355196A (en) | 2001-04-18 |
| CA2336602A1 (en) | 2000-01-13 |
| AU4969499A (en) | 2000-01-24 |
| AU770392C (en) | 2000-01-24 |
| JP2002519384A (en) | 2002-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2230458C2 (en) | Fodder for domestic animals, method for its preparing and therapeutic method for maintaining healthy joints and deterioration of arthritic symptoms in domestic animals | |
| KR900002027B1 (en) | Food composition containing methyl sulfonyl methane and method of using the same | |
| US20120004157A1 (en) | Hydroxyproline compositions and uses thereof | |
| US12128091B2 (en) | Pet food formulation with cannabinoids | |
| CN1286392C (en) | Prevention of dental calculus with polycarboxylic acids | |
| US8703174B2 (en) | Joint preserving nutritional vitamin, mineral and herbal pet supplement | |
| JP2005501043A (en) | Methods for treating joint inflammation, pain, and reduced mobility | |
| US6428817B1 (en) | Companion animal therapeutic treat | |
| AU770392B2 (en) | Companion animal therapeutic treat | |
| BG107626A (en) | Application of benzophenanthridine alcaloids as fodder additive and medicamentous form against intestinal inflammation | |
| Smith et al. | Abnormal bone development and lameness associated with secondary copper deficiency in young cattle | |
| WO1990009179A1 (en) | Treatment of tibial dyschondroplasia | |
| JPWO2006120974A1 (en) | Health food and pharmaceutical composition for improving diseases of cartilage metabolism disorder | |
| JP2001089384A (en) | Feed for treatment for animal | |
| KR100327966B1 (en) | Nutrients containing water-soluble chitosan for pig and using method thereof | |
| Hwang et al. | Flounder skin meal as a potential protein source substitute in the diet of juvenile black rockfish (Sebastes schlegeli) | |
| AU2005200953A1 (en) | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same | |
| JPS63502835A (en) | Immune modulators that improve commercial performance in livestock | |
| WO2009008885A1 (en) | Cholesterol reducing food compositions for animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |